The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
To the Editor:
The US-based, phase IV, multicenter, randomized, doubleblind, placebo-controlled XTEND-CIU (Xolair Treatment Efficacy of LoNger Duration in Chronic Idiopathic Urticaria) study was designed to answer critical questions regarding the role of omalizumab in the treatment of patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) not answered by the omalizumab pivotal trials [1] [2] [3] : (1) What is the efficacy and safety of omalizumab in patients with CIU/CSU treated for 48 weeks? (2) What impact does discontinuation of omalizumab have on patients? (3) What is the persistency of benefit of omalizumab treatment after 24 and 48 weeks? (4) What is the efficacy of omalizumab when reinitiated after discontinuation? This article's Online Repository at www.jacionline.org includes additional details on study design, statistical analysis, patient disposition and characteristics, and safety, as well as supplemental figures.
The XTEND-CIU study enrolled patients aged 12 to 75 years with antihistamine-resistant CIU/CSU and a 7-day Urticaria Activity Score (UAS7) of at least 16 during the 7 days before baseline. The XTEND-CIU study had 2 phases: (1) an initial 24-week open-label period (n 5 205; all patients were given omalizumab 300 mg subcutaneously every 4 weeks), and (2) a follow-on 24-week double-blind phase (n 5 134; patients with a UAS7 of < _6 in the final 2 consecutive weeks of the open-label period were randomized to continue omalizumab or switch to placebo). During the double-blind period, randomized patients with investigator-assessed clinical worsening of CIU/CSU (UAS7 of at least 12 for 2 consecutive weeks) could be transitioned to open-label omalizumab treatment and continued through week 48. Patients used the Urticaria Patient Daily Diary 4, 5 to record symptoms twice daily and completed the paper-based Dermatology Life Quality Index 6 at weeks 24, 36, and 48 of the double-blind period. The primary efficacy end point was the percentage of patients with CIU/CSU clinical worsening (UAS7 of at least 12 for at least 2 consecutive weeks between weeks 24 and 48).
Most placebo-treated patients (60.4%) experienced CIU/CSU relapse versus 21% of omalizumab-treated patients (Fig 1, A) . A separation in time to clinical worsening between omalizumab and placebo was noted as early as 1 month and continued to increase until the end of the double-blind period (P < .0001; see Fig E2 in this article's Online Repository at www.jacionline. org). The proportion of patients with Dermatology Life Quality Index worsening mirrored the primary end point results (Fig 1, B) .
Patients who continued on omalizumab beyond 24 weeks maintained symptom control as evidenced by a clinically insignificant change in average UAS7 (mean change, 1.8; P < .0001). In addition, patients randomized to continue on omalizumab experienced a lower average proportion of angioedema days when compared with patients randomized to placebo (average percentage of angioedema days, 0.8% vs 7.3%, respectively).
The percentage of patients with clinical worsening 12 weeks after omalizumab discontinuation was similar whether the patient had discontinued after 24 weeks of treatment (placebo-treated patients) or 48 weeks of treatment (omalizumab-treated patients who completed 48 weeks of treatment; 23 of 53 [43.4%] vs 32 of 71 [45.1%], respectively; P 5 1.00). Among patients randomized to placebo and re-treated with open-label omalizumab for at least 12 weeks (n 5 18), the mean 6 SD change in UAS7 from time of re-treatment to 12 weeks after re-treatment was -29.5 6 9.6 (95% CI, 234.3 to 224.7; P < .0001; Fig 2) .
During the double-blind period, no new safety signals were identified, including no evidence of allergic reactions associated with stopping and restarting omalizumab. Through 60 weeks of the study, 120 patients reported 324 treatment-emergent adverse events (AEs) and 5 patients reported 6 serious AEs. None of the serious AEs were considered to be related to the study drug. There were no deaths during the study. Twelve patients reported 16 AEs that were causally related to the study drug (see Table E2 in this article's Online Repository at www.jacionline.org). Two anaphylactic events were reported during the open-label period. One protracted anaphylactic event was considered to be related to omalizumab; the second event occurred 28 days after exposure to omalizumab (additional details in this article's Online Repository at www.jacionline.org).
The XTEND-CIU study provides additional evidence on the efficacy and safety of omalizumab over a longer term in patients with CIU/CSU. Continued omalizumab treatment was beneficial to patients both by preventing return of symptoms and by achieving sustained control through 48 weeks of treatment. Furthermore, the percentage of patients experiencing clinical worsening during the 12 weeks after withdrawing treatment was identical in patients treated for 24 weeks before withdrawal and those treated for 48 weeks before withdrawal, suggesting the need to treat beyond 48 weeks. Continued treatment with omalizumab prevents relapse and improves quality of life. Re-treatment, when needed, can be accomplished safely and effectively. Additional real-world studies are needed to confirm the benefits of omalizumab treatment of CIU/CSU for longer than 48 weeks.
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METHODS
The XTEND-CIU study was conducted from May 2015 through January 2016.
AEs were collected throughout the study. Morning and evening itch severity and number of hives scores from the Urticaria Patient Daily Diary E1,E2 were averaged each day and the weekly sum of daily UAS produced a UAS7. The Dermatology Life Quality Index (DLQI) is a 10-item tool that evaluates patients' perception of a skin problem on dermatology-related quality of life. Total scores on the DLQI range from 0 to 30; high scores indicate a high negative impact of a skin problem on patient dermatologyrelated quality of life. The minimally important difference for the DLQI total score is 2.24 to 3.10.
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The primary objective of the XTEND-CIU study was to evaluate the control of CIU/CSU symptoms through 48 weeks of treatment among patients continuing on omalizumab compared with those receiving placebo after an initial 24 weeks of omalizumab treatment. Secondary objectives included the following: (1) evaluation of response to re-treatment with omalizumab in patients with CIU who responded to omalizumab, but experienced recurrence or clinical worsening after therapy withdrawal; (2) evaluation of levels of response to omalizumab after 48 weeks of treatment compared with response after 24 weeks of treatment; and (3) evaluation of omalizumab safety through 48 weeks of treatment in patients with CIU. The proportion of patients experiencing DLQI worsening (increase of > _3 points in DLQI score between weeks 24 and 48) was a prespecified exploratory end point.
Statistical analysis
All patients meeting criteria for randomization, receiving at least 1 dose of blinded study drug, and who had at least 1 postbaseline efficacy assessment were included in the efficacy set (modified intention-to-treat). Those patients who entered the double-blind period without major protocol deviations comprised the per-protocol population. The safety set included all patients who received at least 1 dose of the study drug.
Patients who prematurely discontinued without UAS7 of at least 12 for 2 consecutive weeks before discontinuation were considered to have experienced clinical worsening. Secondary end points included the following: the time to CIU/CSU clinical worsening, the percentage of patients experiencing CIU/CSU clinical worsening defined differently than the primary end point-UAS7 of more than 6 for at least 2 consecutive weeks between week 24 and week 48, the change from randomization (week 24) to week 48 in UAS7, and the change in UAS7 from time of re-treatment to 12 weeks after re-treatment. The proportion of patients experiencing worsening DLQI (increase of > _3 points in DLQI score between weeks 24 and 48) was a prespecified exploratory end point.
Whenever end points were binary, such as the primary end point of the study, counts and proportions of the response were evaluated, accompanied by P values and 95% CIs (using the normal approximation to the binomial distribution). Changes in continuous outcome measures were evaluated using means, SDs, P values, and 95% CIs. Between-group comparisons of binary end points used 2-sided chi-square tests to generate P values, and P values for continuous outcome measures were generated via t tests. Time to CIU/CSU clinical worsening was analyzed using the Kaplan-Meier method and log-rank tests were used to compare the 2 treatment groups. Statistical significance was declared when P was less than .05. Safety data were summarized for all study phases.
To address the secondary objective of evaluating the level of response to omalizumab after 48 weeks of treatment compared with response after 24 weeks of treatment, change in UAS7 from randomization (week 24) to week 48 was analyzed in the context of a 1-sided hypothesis (null hypothesis that the mean of the week 48 2 week 24 UAS7 among omalizumab-treated patients is > _5 with an alternative hypothesis that the average score of this difference is <5). Rejecting this null hypothesis would imply that the mean difference between UAS7 at weeks 24 and 48 among omalizumab-treated patients was not clinically significant. Results were similar to the primary efficacy analysis when the per-protocol population was used for the analysis; CIU/CSU worsening was noted in 58.0% in placebo-treated patients (n 5 50) and 21.3% in omalizumab-treated patients (n 5 80; 95% CI for treatment difference, 252.4% to 219.4%; P <.0001).
RESULTS
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Safety
AEs of special interest included anaphylactic events, as defined by the National Institute of Allergy and Infectious Disease criteria, E4 related to omalizumab; suspected transmission of an infectious agent by the study drug; and cases of potential drug-induced liver injury.
Two anaphylactic events were reported during the XTEND-CIU study. Patient 1 was a 46-year-old woman with a history of CIU/CSU and angioedema, as well as mild, intermittent asthma and a possible viral illness. She had no history of insect, food, or medication allergy and no previous exposure to omalizumab. Approximately 9 hours after receiving her first 300 mg omalizumab dose, she experienced headache, malaise, worsening of hives, itchy throat, stomach cramps, wheezing, and cough. Symptoms escalated and she self-administered epinephrine and went to the emergency department. She received another epinephrine dose intramuscularly, Nyquil, famotidine, prednisone, and hydroxyzine. She was discharged to home with instructions to continue oral steroids and antihistamines. The next evening she experienced facial, throat, lip, and tongue swelling. She self-administered epinephrine and called emergency services. Symptoms had improved when the ambulance arrived and she remained at home. During a study site visit the following day, vital signs included a respiratory rate of 18 and heart rate of 80. The patient appeared uncomfortable and physical examination revealed bilateral conjunctivitis with mild chemosis and diffuse urticaria, primarily at the extremities. She was given prednisone and cetirizine and prescribed an albuterol inhaler, montelukast, and a prednisone taper. She was subsequently discharged from the study. This protracted anaphylactic event was assessed as related to omalizumab.
The second patient was a 26-year-old woman with a history of CIU/CSU, angioedema, allergic rhinitis, amenorrhea, and polycystic ovary syndrome. She had no history of anaphylactic episodes, exposure to omalizumab, or food, insect, or medication allergy. She received cetirizine during the study. Her initial dose of omalizumab was 300 mg and 4 subsequent doses were given every 4 weeks until April 5, 2016 . Approximately 1 month after her fifth dose, she developed anaphylaxis of unknown etiology (severity: grade 4) with facial edema, diffuse urticaria, and throat tightness. The event was associated with wheezing/ bronchospasm, dyspnea, stridor, and acute onset of skin and mucosal illness distinct from findings attributed to CIU/CSU. Treatment included nebulized ipratropium bromide, epinephrine, famotidine, prednisone, and methylprednisolone, and anaphylaxis resolved. She received omalizumab the following day and continued with every-4-week dosing for 4 more doses. Treatment was then stopped because she did not meet randomization criteria for the double-blind phase of the XTEND-CIU study. Further investigation revealed that the patient had experienced previous similar symptoms before entering the study. This anaphylactic event was assessed as not related to omalizumab.
Eight patients (omalizumab, n 5 1; placebo, n 5 2; not randomized, n 5 5) permanently discontinued from the study because of an AE and 7 patients (omalizumab, n 5 1; placebo, n 5 2; not randomized, n 5 4) permanently discontinued the study drug because of an AE. ED, Emergency department; TEAE, treatment-emergent adverse event.
